Better Context → Better Decisions

Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.

Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Sep 08 | 2020Thoughts on Autolus's CAR-T Program; Q2 2020 Earnings Call Access Free Blast

Posted in: Autologous, CAR-T, CD19 Sep 04 | 2020Gilead Highlights No Impact of COVID-19 on Yescarta Sales; Two New LCM Initiatives for Yescarta; Q2 2020 Earnings Call Summary Access Free Blast

Posted in: Autologous, BCMA, CAR-T Sep 03 | 2020bluebird bio Highlights Ide-cel Resubmission; Q2 2020 Earnings Call Access Free Blast

Posted in: Allogeneic, BCMA, CAR-T, CD19 Sep 01 | 2020Thoughts on Allogene’s AlloCAR Program; Q2 2020 Earnings Call Summary Access Free Blast

Posted in: BCMA, CAR-T, CD19 Sep 01 | 2020BMS Highlights Ide-cel FDA Re-submission; Q2 2020 Earnings Call Access Free Blast

Posted in: Autologous, CAR-T, CD19 Aug 31 | 2020Thoughts on Gilead's Recent FDA Approval for Tecartus (KTE-X19) in R/R Mantle Cell Lymphoma Access Free Blast

Posted in: Autologous, BCMA, CAR-T Jul 30 | 2020BMS and bluebird bio Resubmit Ide-cel to FDA; Dynamic H1 2021 BCMA Launch Environment Expected with Janssen Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jul 03 | 2020Novartis Ph1b PORTIA Results Presented at Virtual AACR II Access Free Blast

Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Jul 03 | 2020Two New Gracell Early Ph1 Trials in MM and NHL Posted Access Free Blast

Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, CD22 Jun 17 | 2020Novartis Discusses Their Activated Rapid Manufacturing Program and Kymriah in the Community Setting Access Free Blast

Posted in: Autologous, CAR-T, CD19 Jun 12 | 2020Gilead Announces EMA Approval for End-to-End Yescarta CAR-T Manufacturing at Amsterdam Facility Access Free Blast

Posted in: Allogeneic, CAR-T, CD19 Jun 09 | 2020New Pivotal ALLO-501A (ALPHA-2) Trial in DLBCL Posted Access Free Blast

Posted in: Autologous, CAR-T, CD19, CD22 Jun 05 | 2020Autolus Ph1 ALEXANDER Results and ASCO 2020 Investor Call Summary Access Free Blast

Posted in: Allogeneic, CAR-T, CD19 Jun 01 | 2020Allogene ALLO-501 Ph1 ALPHA Results and ASCO 2020 Investor Call Summary Access Free Blast

Posted in: Autologous, CD19 May 29 | 2020New Autolus AUTO1 Pivotal Trial in Adult ALL Posted Access Free Blast

Posted in: Allogeneic, Autologous, CAR-T, CD19 May 29 | 2020Autolus Provides Update on CAR-T Program; Q1 2020 Call Summary Access Free Blast

Posted in: Allogeneic, BCMA, CAR-T, CD19 May 28 | 2020Thoughts on Allogene CAR-T Pipeline Update; Q1 2020 Call Summary Access Free Blast

Posted in: BCMA, CAR-T, CD19 May 12 | 2020Liso-Cel PDUFA 3-Month Delay; BMS Q1 2020 Call Summary Access Free Blast

« prev 1 … 30 31 32

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

Contact UsLog In

error: Content is protected !!